Eli Lilly viewed positively despite Mounjaro, Zepbound disappointment - BoAProactive Investors • 10/31/24
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell shortCNBC • 10/30/24
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain ChallengesSeeking Alpha • 10/30/24
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock TanksZacks Investment Research • 10/30/24
Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/24
Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound SalesForbes • 10/30/24
Eli Lilly tumbles as weight loss drug sales underwhelm, guidance slashedProactive Investors • 10/30/24
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall ShortInvestors Business Daily • 10/30/24